Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siliq in Moderate to Severe Plaque Psoriasis After IL-17A Failure
NCT03403036Phase 4Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Oct 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brodalumab in plaque psoriasis, sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Physician's Global Assessment 0 or 1 at 16 weeks. Started Oct 2017; status: completed.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03403036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403036.